It was a pivotal moment that has turned into a new era for cancer immunotherapy. On April 17, 2012, Children's Hospital of Philadelphia researchers for the first time treated a pediatric patient with a cellular therapy that used her own reprogrammed immune cells, called T cells, to attack her aggressive form of blood cancer.
Our researchers whose work is at the cross section between injury and neurodevelopmental or intellectual disabilities have a unique vantage point when studying the driving safety of adolescents with autism spectrum disorder (ASD). The Research Institute is home to two of the most highly regarded autism and pediatric injury research centers in the world.
The Research Institute's Annual Report 2016, which you can find here, features dozens of inspiring and engaging stories that highlight new programs, our commitment to collaboration and excellence, and how our investigators and staff are leading the way in innovation and driving change in children's care.
By Bryan A. Wolf, MD, PhD, Chief Scientific Officer and Director of the Research Institute
Every space flight mission requires a carefully planned trajectory, and similarly the national Cancer Moonshot initiative needed a scientific roadmap to reach its ambitions of accelerating the prevention, diagnosis, and treatment of cancer to make a decade of progress in the next five years. In September,
Diversity has long been a key driver of achievement at The Children’s Hospital of Philadelphia Research Institute, particularly when it comes to innovation and performing more accurate and inclusive research.
